KIDS Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
OrthoPediatrics News
KIDS FAQ
What was OrthoPediatrics Corp’s price range in the past 12 months?
Currently, no data Available
What is OrthoPediatrics Corp’s market cap?
OrthoPediatrics Corp’s market cap is $8.89B.
When is OrthoPediatrics Corp’s upcoming earnings report date?
OrthoPediatrics Corp’s upcoming earnings report date is Aug 04, 2026 which is in 5 days.
How were OrthoPediatrics Corp’s earnings last quarter?
OrthoPediatrics Corp released its earnings results on Apr 30, 2026. The company reported -$7.848 earnings per share for the quarter, beating the consensus estimate of -$7.935 by $0.087.
Is OrthoPediatrics Corp overvalued?
According to Wall Street analysts OrthoPediatrics Corp’s price is currently Undervalued.
Does OrthoPediatrics Corp pay dividends?
OrthoPediatrics Corp does not currently pay dividends.
What is OrthoPediatrics Corp’s EPS estimate?
OrthoPediatrics Corp’s EPS estimate is -5.27.
How many shares outstanding does OrthoPediatrics Corp have?
Currently, no data Available
What happened to OrthoPediatrics Corp’s price movement after its last earnings report?
OrthoPediatrics Corp reported an EPS of -$7.848 in its last earnings report, beating expectations of -$7.935. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of OrthoPediatrics Corp?
Currently, no hedge funds are holding shares in MX:KIDS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OrthoPediatrics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$437.11 (― Upside)
$437.11 (― Upside)
Blogger Sentiment
Bullish
MX:KIDS Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.79%
Trailing 12-Months
Company Description
OrthoPediatrics Corp
OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children affected by orthopedic conditions across the United States and internationally. The company's diverse offerings span products for trauma and deformity correction, surgical systems for spinal deformities such as scoliosis, and solutions for sports medicine, among others. Their comprehensive product line features items like PediLoc, PediPlates, various cannulated screws, the PediFlex and PediNail systems, PediLoc tibia, advanced anterior cruciate ligament reconstruction systems, specialized locking cannulated blades and proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, the Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and the ApiFix Mid-C system. OrthoPediatrics Corp. primarily serves the pediatric orthopedic market, directly assisting pediatric orthopedic surgeons and caregivers. The company was founded in 2006 and maintains its headquarters in Warsaw, Indiana.
KIDS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong execution and acceleration across several strategic fronts: double-digit revenue growth (13% YoY), a return to positive adjusted EBITDA, >20% OPSB growth, international acceleration, multiple promising beta launches (3P Hip, Vertiglyde) and EU MDR approvals. Management raised full-year revenue guidance and reaffirmed a path to adjusted EBITDA of ~$25M and free-cash-flow breakeven in 2026. Key short-term headwinds and risks include weather-related clinic disruptions that shifted some demand into Q2, continued GAAP/non-GAAP net losses, higher operating expense levels, lower set deployments versus prior-year (by design), and timing uncertainty around set availability and product rollouts. On balance, the strategic momentum, margin improvement and guidance raise outweigh the near-term challenges and execution/timing risks.View all MX:KIDS earnings summaries